Harvard Pilgrim Signs Outcomes-Based Contracts with AstraZeneca

NEC member Harvard Pilgrim HealthCare recently signed two outcomes-based contracts with AstraZeneca for medicines used to treat Type 2 Diabetes and acute coronary disease.

Outcomes-based contracts allow Harvard Pilgrim to pay for the drugs based on their value to a patient rather than the amount of medicine provided by AstraZeneca. One of the contracts is for the drug Brilinta, which is used to lower the risk of a patient having another heart attack or dying from a heart attack. Doctors will monitor whether there is a reduction in patients hospitalized due to a repeat acute coronary event while using Brilinta. The other medicine Harvard Pilgrim signed a contract for is Bydureon, which is used to control a Type 2 Diabetes patient’s blood glucose levels. Doctors will measure the drug’s effectiveness by tracking if patients are able to reach a predetermined goal blood glucose level.

“Linking the ultimate cost of these medicines to their real-world clinical effectiveness really puts patients at the center of focus,” said Michael Sherman, Harvard Pilgrim’s Chief Medical Officer. “Real world performance may differ from what is observed in well-controlled clinical trials, and the willingness of pharmaceutical companies like AstraZeneca to go at risk for delivering on these outcomes sends a positive message to health plans, prescribing physicians, and patients.”

The New England Council congratulates Harvard Pilgrim on the signing of this new agreement that will benefit patients, physicians, and the company overall. Read more in Worcester Business Journal and Business Wire.

img_side
mask_sidebar
Recently from the Blog

CMBG3 to Host Webinar on California Prop 65 Changes

03/3/2021 | Read Post

Dean College President Rooney Honored by Indiana Univeristy

02/22/2021 | Read Post

In the News

NEC Elects Six Respected Regional Business Leaders to Board of Directors

09/28/2020 | Read Press Release

NEC Announces 2020 New Englanders of the Year

08/25/2020 | Read Press Release